GeneDx Holdings (WGS) Misses Q2 EPS by 46c; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
GeneDx (WGS) PT Raised to $45 at BTIG
July 31, 2024 4:57 AM EDTBTIG analyst Mark Massaro raised the price target on GeneDx (NASDAQ: WGS) to $45.00 (from $35.00) while maintaining a Buy rating.
The analyst comments "Shares of WGS are indicating up +10% AH following another strong quarterly beat-and-raise. WGS drove a ~$10M revenue beat (~16%... More
